Pretreatment of AML/MDS patients’ WB samples with blast-modulating Kits (vs. no Kits) increased the frequencies of DC/DCleu, which ultimately increased the frequencies of (leukemia-specific degranulating or cytokine-producing) β7-expressing T- or NK/CIK-cell subtypes after T-cell-enriched MLC. The gene discussed is CD80; the disease is myelodysplastic syndrome.